The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses

Pre-existing cross-reactive immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by several studies. In particular, regions of high homology between SARS-CoV-2 and common cold coronaviruses have been highlighted as...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Murray, SM, Ansari, AM, Frater, J, Klenerman, P, Dunachie, S, Barnes, E, Ogbe, A
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Springer Nature 2022

Eitemau Tebyg

SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study
gan: Ward, V, et al.
Cyhoeddwyd: (2022)

SARS-CoV-2 antibody responses post-vaccination in UK healthcare workers with pre-existing medical conditions: a cohort study
gan: Eleanor Barnes, et al.
Cyhoeddwyd: (2022-12-01)

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
gan: Caiqin Hu, et al.
Cyhoeddwyd: (2022-09-01)

IgM responses following SARS-CoV-2 vaccination: insights into protective and pre-existing immunity
gan: Judith Fraussen
Cyhoeddwyd: (2022-03-01)

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
gan: Cecilia Jay, et al.
Cyhoeddwyd: (2023-08-01)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
gan: Skelly, DT, et al.
Cyhoeddwyd: (2021)

Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity
gan: Rajat Desikan, et al.
Cyhoeddwyd: (2022-10-01)

Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination
gan: Alok R. Amraotkar, et al.
Cyhoeddwyd: (2022-08-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
gan: Larissa Henze, et al.
Cyhoeddwyd: (2023-01-01)

Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
gan: Jay, C, et al.
Cyhoeddwyd: (2023)

mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals
gan: Stephanie Longet, et al.
Cyhoeddwyd: (2022-09-01)

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus
gan: Fidler, S, et al.
Cyhoeddwyd: (2022)

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
gan: Donal T. Skelly, et al.
Cyhoeddwyd: (2021-08-01)

Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
gan: José L. Casado, et al.
Cyhoeddwyd: (2022-08-01)

Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children
gan: Nina Li, et al.
Cyhoeddwyd: (2022-10-01)

Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Siberian Populations
gan: Olga N. Shaprova, et al.
Cyhoeddwyd: (2023-12-01)

Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals
gan: Norihide Jo, et al.
Cyhoeddwyd: (2021-08-01)

SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination
gan: Shishan Teng, et al.
Cyhoeddwyd: (2024-02-01)

Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
gan: Pedro A. Reche
Cyhoeddwyd: (2020-10-01)

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
gan: Barnes, E, et al.
Cyhoeddwyd: (2023)

SARS-CoV-2 and Pre-existing Vascular Diseases: Guilt by Association?
gan: Grigorios Voulalas, et al.
Cyhoeddwyd: (2021-05-01)

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
gan: Sonia Tejedor Vaquero, et al.
Cyhoeddwyd: (2021-09-01)

Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020
gan: Edmilson F. de Oliveira-Filho, et al.
Cyhoeddwyd: (2022-04-01)

Immune Response to SARS-CoV-2 Vaccines
gan: Navya Bellamkonda, et al.
Cyhoeddwyd: (2022-06-01)

Pre-existing cross-reactive neutralizing activity against SARS-CoV-2 and seasonal coronaviruses prior to the COVID-19 pandemic (2014-2019) with limited immunity against recent emerging SARS-CoV-2 variants, Vietnam
gan: Thi Thanh Ngan Nguyen, et al.
Cyhoeddwyd: (2024-02-01)

Cross-reactive immunity to SARS-CoV-2 and related coronaviruses
gan: Jay, C
Cyhoeddwyd: (2023)

Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live-attenuated influenza vaccines in UK adolescents
gan: Cecilia Jay, et al.
Cyhoeddwyd: (2023-10-01)

Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity
gan: Abdullah M. Izmirly, et al.
Cyhoeddwyd: (2020-06-01)

Poor antibody responses to SARS-CoV-2 infection or vaccination are associated with high re-infection rates in haemodialysis and renal transplant patients
gan: Shankar, S, et al.
Cyhoeddwyd: (2021)

Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations
gan: Marc Souris, et al.
Cyhoeddwyd: (2022-10-01)

Pre-Existing Microbiome Signature in a SARS-CoV-2 Discordant Family
gan: Sabine Hazan
Cyhoeddwyd: (2022-02-01)

SARS-CoV-2 in pre-existing autoimmune myasthenia gravis: An institutional experience
gan: Nitisha Goyal, et al.
Cyhoeddwyd: (2021-03-01)

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection
gan: Martina Milighetti, et al.
Cyhoeddwyd: (2023-06-01)

Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination
gan: Krystallenia Paniskaki, et al.
Cyhoeddwyd: (2022-10-01)

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
gan: Mina Psichogiou, et al.
Cyhoeddwyd: (2021-06-01)

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
gan: Marloes Grobben, et al.
Cyhoeddwyd: (2021-11-01)

Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses
gan: Runhong Zhou, et al.
Cyhoeddwyd: (2022-01-01)

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
gan: Xiuyuan Ou, et al.
Cyhoeddwyd: (2020-03-01)

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
gan: Willett, BJ, et al.
Cyhoeddwyd: (2022)

The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants
gan: Thompson, RN, et al.
Cyhoeddwyd: (2023)